Published in Drug Week, July 8th, 2005
"Gene therapy for prostate cancer may be realized through transduction of whole genes, such as prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA), into immunotherapeutic dendritic cells (DCs). An oncoretroviral vector encoding human PSMA and a bicistronic oncoretroviral vector encoding human PSA and cell surface CD25 cDNAs were constructed," researchers in Canada report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.